However, an exploratory subgroup analysis of CPS ≥ 1 with 22C3 antibodies showed a trend toward better use of avelumab (median OS, 14.9 months vs. 11.6 months; HR, 0.72).
1
—
—
However, an exploratory subgroup analysis of CPS ≥ 1 with 22C3 antibodies showed a trend toward better use of avelumab (median OS, 14.9 months vs. 11.6 months; HR, 0.72).